Claire C. Kim

All Publications

• Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026. Cells Poe, J., Kim, C., Coleman, C., Nguyen, H., Velazhahan, V., Bergsneider, B., Sanker, V., Kim, S., Chen, Y., Abikenari, M., Choi, J., Lim, M. 2026; 15 (6)

  Abstract

  Glioblastoma (GBM) persists as one of the greatest challenges in the treatment of human cancer, despite extensive efforts to leverage the therapeutic potential of immunotherapy. While checkpoint blockade and other forms of immunotherapy have revolutionized the treatment of various cancers, their therapeutic efficacy in GBM has been hindered by the profound immunosuppressive environment, spatial heterogeneity, and dynamic immune metabolic challenges associated with the tumor microenvironment. In this review, we will synthesize recent advances and insights to develop a next-generation framework for GBM immunotherapy based on systems biology approaches to understanding the complex interplay between GBM and the immune system, as opposed to single-axis approaches to immune activation and modulation. We will discuss how the functional competence of the interferon system, myeloid antigen presentation status, T-cell clone status, spatial organization of the immune microenvironment, and resource competition between GBM and the immune system dictate therapeutic responsiveness. Furthermore, the current paper elucidates how recent advances in spatial transcriptomics, single-cell analysis, and high-parameter imaging enable us to understand how immune phenotype status varies across GBM regions and treatment status, and how this information can be used to develop predictive and pharmacodynamic biomarkers of therapeutic efficacy and failure. We will then discuss how these advances form the basis for rational combination approaches to GBM immunotherapy, which involve the integration of checkpoint blockade with metabolic reprogramming, myeloid modulation, and interferon system reactivation, and how artificial intelligence-based analytics and adaptive clinical trial design can guide the development of biomarker-based therapeutic selection approaches.

  View details for DOI 10.3390/cells15060561

  View details for PubMedID 41892350

  View details for PubMedCentralID PMC13025625

• Ophthalmic and Ocular Motor Features of Patients with Spinocerebellar Ataxia Type 7 Association for Research in Vision and Ophthalmology Kim, C. C., Zalewski, C., Jeffrey, B. G., Poling, G. L., Blain, D., La Spada, A. R., Brooks, B. P., Huryn, L. 2025
• Supervised Inhalation Sites: Preventing Overdose and Reducing Health Inequities among People Who Use Drugs. Substance use & misuse Lu, A., Kim, C., Rosen, J. G., Thompson, E., Tardif, J., Welwean, R., Park, J. N. 2024; 59 (4): 520-526

  Abstract

  Policy and research on the implementation of services for people who inhale drugs lag behind similar efforts for people who inject drugs, limiting access to adequate harm reduction resources for people who inhale drugs. This commentary considers why supervised inhalation sites (SIS) are needed, highlights operational characteristics of four existing services, and advocates for future SIS research. Our hope is to encourage the expansion of SIS worldwide for overdose prevention and reduction of health inequities. Given the limited literature regarding SIS, more extensive study of these programs is warranted to incorporate inhalation into the implementation of supervised consumption sites to provide fair opportunities for all people who use drugs to do so safely without fear of stigma and overdose.

  View details for DOI 10.1080/10826084.2023.2287195

  View details for PubMedID 38044494

  View details for PubMedCentralID PMC10922979